Lowest Price Guaranteed From USD 3,499
The concept of undruggable targets is a misconception. All molecules, including proteins, receptors, lipids and antibodies, can be targeted. However, new technology platforms are required to develop drug candidates against difficult-to-modulate targets.
-Chief Executive Officer, a Spain based company
The global cancer therapeutics market size is estimated to be worth $11.9 billion by 2035 and is expected to grow at CAGR of 84% during the forecast period. Cancer therapeutics continues to be one of the most active segments, in terms of drug development efforts, within the pharmaceutical industry. In fact, in the past five years, USFDA has approved more than 70 drugs for the treatment of different types of cancer. However, there is still a pressing need to develop more specific and potent therapeutics to combat this complex, life threatening clinical condition. According to the National Institutes of Health, the economic burden of cancer care in the US was estimated to be over USD 147 billion in 2017. As the global population continues to increase, the number of cancer patients is likely to rise as well; by 2030, it is estimated that about 21.6 million people are likely to be newly diagnosed with the disease. Thereby, the overall global economic burden related to the disease is anticipated to increase significantly in the foreseen future.
Conventional cancer treatments, such as chemotherapy and radiation therapy are associated with several side effects. Their non-specific nature has been shown to have severe detrimental effects on patients’ quality of life. Current drug development initiatives are focused on targeted therapies against specific oncogenic mutations that are responsible for disease development and / or progression. Over the years, several targeted drugs have been designed against specific proteins, such as human epidermal growth factor (HER2), BCR-ABL protein kinase and vascular endothelial growth factor (VEGF). However, certain biological targets have long eluded drug development efforts and, for a considerable period of time, have been reported to be undruggable. One such target is Ras family, which has been identified to a play critical role in oncogenesis. Scientific literature suggests that the RAS gene is mutated across about 30% of cancer types; the mutation is known to be present in about 90% of pancreatic cancers, over 50% of colorectal cancers and 35% of lung cancers. Likewise, there are several other targets that have not yet been successfully drugged and researchers are making significant efforts to identify novel approaches to target them.
Advances in drug discovery and development technologies / platforms have increased the likelihood of targeting a number of the abovementioned types of biological targets. As a result, novel product development opportunities have emerged and are likely to benefit both drug developers and investors alike. Ongoing R&D is focused on the development of treatment modalities that can also combat complications, such as off target toxicities and disease relapse, which are associated with the current standard of care therapies. As various clinical stage candidates progress towards advanced stages of development, we expect the oncology market to witness aggressive market growth over the coming years.
Examples of key oncology pharmaceutical companies engaged in cancer therapeutics market targeting the undruggable cancer targets (which have also been profiled in this market report; the complete list of oncology pharmaceutical companies is available in the full report) include Boston Biomedical, GLG Pharma, GlobeImmune, Ionis Pharmaceuticals, Onconova Therapeutics and Targovax. This market report includes an easily searchable excel database of all the oncology pharmaceutical companies developing cancer therapeutics against undruggable cancer targets, worldwide.
Several recent developments have taken place in the global cancer therapeutics market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our cancer therapeutics market analysis.
The ‘Cancer Therapeutics Market: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030’ market report provides a comprehensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the cancer therapeutics market. It features an elaborate discussion on the future potential of cancer therapeutics market, focusing on phosphatases, transcription factors, small GTPases (specifically Ras family) and undruggable G-protein coupled receptors (GPCRs). One of the key objectives of the market research report was to review and quantify the future opportunity for the ongoing product development programs of both small and big pharmaceutical firms.
Amongst other elements, the market research report features:
The key objective of cancer therapeutics market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for cancer therapeutics market during the forecast period. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to long-term, for the forecast period 2018 to 2030. To account for the uncertainties associated with the development of cancer therapeutics and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. The opinions and insights presented in this market research report were influenced by discussions conducted with several key players in cancer therapeutics market. The market report features detailed transcripts of interviews held with Amotz Shemi (CEO, Silenseed), Brian Frenzel (President and CEO, Tosk), Miguel Vega (CEO, Allinky Biopharma) and Stephen Franklin (CEO, Evgen Pharma). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.